XML 17 R9.htm IDEA: XBRL DOCUMENT
v3.25.2

Intangible assets | 6 Months Ended
--- | ---
Jun. 30, 2025
Intangible assets |
Intangible assets | Note 2: Intangible assets The acquisition of EsoBiotec completed on 19 May 2025. The transaction is recorded as an asset acquisition based upon the concentration test permitted under IFRS 3 ‘Business Combinations’, with consideration and net assets acquired of $403 m, which included intangible assets acquired of $426 m, current payables of $29 m, $4 m of cash and cash equivalents and current receivables of $2 m. Contingent consideration of up to $575 m could be paid on achievement of regulatory milestones, those liabilities will be recorded when the relevant regulatory milestone is achieved. ​

X
- References No definition available. + Details
Name: | ifrs-full_DisclosureOfIntangibleAssetsAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for intangible assets. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 38 -IssueDate 2024-01-01 -Section Disclosure -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS38_g118-128_TI -URIDate 2024-03-27 + Details
Name: | ifrs-full_DisclosureOfIntangibleAssetsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration